APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antivirals

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Antivirals Market Outlook and Growth Opportunities 2026

21 December 2025199 pages

Choose your research edition.

Industry ResearchAntivirals Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Antivirals Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Antivirals Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antivirals Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Antivirals Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Antivirals market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antivirals is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Antivirals market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Antivirals market include Teva Pharmaceutical Industries, Johnson & Johnson, Merck, Mylan, Gilead Sciences, GSK, AbbVie, F. Hoffmann-La Roche and Dr Reddy’s, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antivirals market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antivirals and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antivirals sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antivirals market size, projected growth trends, production technologies, key applications, and end-use industries.

Antivirals Segment by Company

Teva Pharmaceutical Industries

Johnson & Johnson

Merck

Mylan

Gilead Sciences

GSK

AbbVie

F. Hoffmann-La Roche

Dr Reddy’s

Cipla

Bristol-Myers-Squibb

Aurobindo Pharma

Antivirals Segment by Type

Generic

Branded

Antivirals Segment by Application

HIV

Influenza

Hepatitis

HSV

Antivirals Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Antivirals status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Antivirals market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Antivirals significant trends, drivers, influence factors in global and regions.

6. To analyze Antivirals competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antivirals market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antivirals and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antivirals.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antivirals market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Antivirals industry.

Chapter 3: Detailed analysis of Antivirals manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Antivirals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Antivirals in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Antivirals Industry Trends Table 2. Antivirals Industry Drivers Table 3. Antivirals Industry Opportunities and Challenges Table 4. Antivirals Industry Restraints Table 5. Global Antivirals Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Antivirals Revenue Share by Company (2021-2026) Table 7. Global Antivirals Sales Volume by Company (k tons) & (2021-2026) Table 8. Global Antivirals Sales Volume Share by Company (2021-2026) Table 9. Global Antivirals Average Price (US$/ton) of Company (2021-2026) Table 10. Global Antivirals Company Ranking, (2024-2026) & (USD Million) Table 11. Global Antivirals Key Company Manufacturing Base & Headquarters Table 12. Global Antivirals Company, Product Type & Application Table 13. Global Antivirals Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Antivirals by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Generic Table 18. Significant Companies of Branded Table 19. Global Antivirals Sales Volume by Type 2021 VS 2025 VS 2032 (k tons) Table 20. Global Antivirals Sales Volume by Type (2021-2026) & (k tons) Table 21. Global Antivirals Sales Volume by Type (2027-2032) & (k tons) Table 22. Global Antivirals Sales Volume Share by Type (2021-2026) Table 23. Global Antivirals Sales Volume Share by Type (2027-2032) Table 24. Global Antivirals Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Antivirals Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Antivirals Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Antivirals Sales Value Share by Type (2021-2026) Table 28. Global Antivirals Sales Value Share by Type (2027-2032) Table 29. Significant Companies of HIV Table 30. Significant Companies of Influenza Table 31. Significant Companies of Hepatitis Table 32. Significant Companies of HSV Table 33. Global Antivirals Sales Volume by Application 2021 VS 2025 VS 2032 (k tons) Table 34. Global Antivirals Sales Volume by Application (2021-2026) & (k tons) Table 35. Global Antivirals Sales Volume by Application (2027-2032) & (k tons) Table 36. Global Antivirals Sales Volume Share by Application (2021-2026) Table 37. Global Antivirals Sales Volume Share by Application (2027-2032) Table 38. Global Antivirals Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Antivirals Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Antivirals Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Antivirals Sales Value Share by Application (2021-2026) Table 42. Global Antivirals Sales Value Share by Application (2027-2032) Table 43. Global Antivirals Sales by Region: 2021 VS 2025 VS 2032 (k tons) Table 44. Global Antivirals Sales by Region (2021-2026) & (k tons) Table 45. Global Antivirals Sales Market Share by Region (2021-2026) Table 46. Global Antivirals Sales by Region (2027-2032) & (k tons) Table 47. Global Antivirals Sales Market Share by Region (2027-2032) Table 48. Global Antivirals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Antivirals Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Antivirals Sales Value Share by Region (2021-2026) Table 51. Global Antivirals Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Antivirals Sales Value Share by Region (2027-2032) Table 53. Global Antivirals Market Average Price (US$/ton) by Region (2021-2026) Table 54. Global Antivirals Market Average Price (US$/ton) by Region (2027-2032) Table 55. Global Antivirals Sales by Country: 2021 VS 2025 VS 2032 (k tons) Table 56. Global Antivirals Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Antivirals Sales by Country (2021-2026) & (k tons) Table 58. Global Antivirals Sales Market Share by Country (2021-2026) Table 59. Global Antivirals Sales by Country (2027-2032) & (k tons) Table 60. Global Antivirals Sales Market Share by Country (2027-2032) Table 61. Global Antivirals Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Antivirals Sales Value Market Share by Country (2021-2026) Table 63. Global Antivirals Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Antivirals Sales Value Market Share by Country (2027-2032) Table 65. Teva Pharmaceutical Industries Company Information Table 66. Teva Pharmaceutical Industries Business Overview Table 67. Teva Pharmaceutical Industries Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 68. Teva Pharmaceutical Industries Antivirals Product Portfolio Table 69. Teva Pharmaceutical Industries Recent Development Table 70. Johnson & Johnson Company Information Table 71. Johnson & Johnson Business Overview Table 72. Johnson & Johnson Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 73. Johnson & Johnson Antivirals Product Portfolio Table 74. Johnson & Johnson Recent Development Table 75. Merck Company Information Table 76. Merck Business Overview Table 77. Merck Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 78. Merck Antivirals Product Portfolio Table 79. Merck Recent Development Table 80. Mylan Company Information Table 81. Mylan Business Overview Table 82. Mylan Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 83. Mylan Antivirals Product Portfolio Table 84. Mylan Recent Development Table 85. Gilead Sciences Company Information Table 86. Gilead Sciences Business Overview Table 87. Gilead Sciences Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 88. Gilead Sciences Antivirals Product Portfolio Table 89. Gilead Sciences Recent Development Table 90. GSK Company Information Table 91. GSK Business Overview Table 92. GSK Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 93. GSK Antivirals Product Portfolio Table 94. GSK Recent Development Table 95. AbbVie Company Information Table 96. AbbVie Business Overview Table 97. AbbVie Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 98. AbbVie Antivirals Product Portfolio Table 99. AbbVie Recent Development Table 100. F. Hoffmann-La Roche Company Information Table 101. F. Hoffmann-La Roche Business Overview Table 102. F. Hoffmann-La Roche Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 103. F. Hoffmann-La Roche Antivirals Product Portfolio Table 104. F. Hoffmann-La Roche Recent Development Table 105. Dr Reddy’s Company Information Table 106. Dr Reddy’s Business Overview Table 107. Dr Reddy’s Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 108. Dr Reddy’s Antivirals Product Portfolio Table 109. Dr Reddy’s Recent Development Table 110. Cipla Company Information Table 111. Cipla Business Overview Table 112. Cipla Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 113. Cipla Antivirals Product Portfolio Table 114. Cipla Recent Development Table 115. Bristol-Myers-Squibb Company Information Table 116. Bristol-Myers-Squibb Business Overview Table 117. Bristol-Myers-Squibb Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 118. Bristol-Myers-Squibb Antivirals Product Portfolio Table 119. Bristol-Myers-Squibb Recent Development Table 120. Aurobindo Pharma Company Information Table 121. Aurobindo Pharma Business Overview Table 122. Aurobindo Pharma Antivirals Sales (k tons), Value (US$ Million), Price (US$/ton) and Gross Margin (2021-2026) Table 123. Aurobindo Pharma Antivirals Product Portfolio Table 124. Aurobindo Pharma Recent Development Table 125. Key Raw Materials Table 126. Raw Materials Key Suppliers Table 127. Antivirals Distributors List Table 128. Antivirals Customers List Table 129. Research Programs/Design for This Report Table 130. Authors List of This Report Table 131. Secondary Sources Table 132. Primary Sources List of Figures Figure 1. Antivirals Product Image Figure 2. Global Antivirals Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antivirals Sales Value (2021-2032) & (US$ Million) Figure 4. Global Antivirals Sales (2021-2032) & (k tons) Figure 5. Global Antivirals Sales Average Price (US$/ton) & (2021-2032) Figure 6. Global Antivirals Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Generic Image Figure 10. Branded Image Figure 11. Global Antivirals Sales Volume by Type (2021 VS 2025 VS 2032) & (k tons) Figure 12. Global Antivirals Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Antivirals Sales Volume Share by Type (2021-2032) Figure 14. Global Antivirals Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Antivirals Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Antivirals Sales Value Share by Type (2021-2032) Figure 17. HIV Image Figure 18. Influenza Image Figure 19. Hepatitis Image Figure 20. HSV Image Figure 21. Global Antivirals Sales Volume by Application (2021 VS 2025 VS 2032) & (k tons) Figure 22. Global Antivirals Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Antivirals Sales Volume Share by Application (2021-2032) Figure 24. Global Antivirals Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Antivirals Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Antivirals Sales Value Share by Application (2021-2032) Figure 27. Global Antivirals Sales by Region: 2021 VS 2025 VS 2032 (k tons) Figure 28. Global Antivirals Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Antivirals Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Antivirals Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Antivirals Sales Value (2021-2032) & (US$ Million) Figure 32. North America Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Antivirals Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Antivirals Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Antivirals Sales Value (2021-2032) & (US$ Million) Figure 38. South America Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Antivirals Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Antivirals Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Antivirals Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Antivirals Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Antivirals Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Antivirals Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Antivirals Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Generic
  • Branded
Applications
  • HIV
  • Influenza
  • Hepatitis
  • HSV
Companies covered
  • Teva Pharmaceutical Industries
  • Johnson & Johnson
  • Merck
  • Mylan
  • Gilead Sciences
  • GSK
  • AbbVie
  • F. Hoffmann-La Roche
  • Dr Reddy’s
  • Cipla
  • Bristol-Myers-Squibb
  • Aurobindo Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Antivirals Sales Value (2021-2032)
  4. 1.2.2 Global Antivirals Sales Volume (2021-2032)
  5. 1.2.3 Global Antivirals Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Antivirals Market Dynamics
  1. 2.1 Antivirals Industry Trends
  2. 2.2 Antivirals Industry Drivers
  3. 2.3 Antivirals Industry Opportunities and Challenges
  4. 2.4 Antivirals Industry Restraints
3 Antivirals Market by Company
  1. 3.1 Global Antivirals Company Revenue Ranking in 2025
  2. 3.2 Global Antivirals Revenue by Company (2021-2026)
  3. 3.3 Global Antivirals Sales Volume by Company (2021-2026)
  4. 3.4 Global Antivirals Average Price by Company (2021-2026)
  5. 3.5 Global Antivirals Company Ranking (2024-2026)
  6. 3.6 Global Antivirals Company Manufacturing Base and Headquarters
  7. 3.7 Global Antivirals Company Product Type and Application
  8. 3.8 Global Antivirals Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Antivirals Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Antivirals Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Antivirals Market by Type
  1. 4.1 Antivirals Type Introduction
  2. 4.1.1 Generic
  3. 4.1.2 Branded
  4. 4.2 Global Antivirals Sales Volume by Type
  5. 4.2.1 Global Antivirals Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antivirals Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Antivirals Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Antivirals Sales Value by Type
  9. 4.3.1 Global Antivirals Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antivirals Sales Value by Type (2021-2032)
  11. 4.3.3 Global Antivirals Sales Value Share by Type (2021-2032)
5 Antivirals Market by Application
  1. 5.1 Antivirals Application Introduction
  2. 5.1.1 HIV
  3. 5.1.2 Influenza
  4. 5.1.3 Hepatitis
  5. 5.1.4 HSV
  6. 5.2 Global Antivirals Sales Volume by Application
  7. 5.2.1 Global Antivirals Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Antivirals Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Antivirals Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Antivirals Sales Value by Application
  11. 5.3.1 Global Antivirals Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Antivirals Sales Value by Application (2021-2032)
  13. 5.3.3 Global Antivirals Sales Value Share by Application (2021-2032)
6 Antivirals Regional Sales and Value Analysis
  1. 6.1 Global Antivirals Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antivirals Sales by Region (2021-2032)
  3. 6.2.1 Global Antivirals Sales by Region: 2021-2026
  4. 6.2.2 Global Antivirals Sales by Region (2027-2032)
  5. 6.3 Global Antivirals Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Antivirals Sales Value by Region (2021-2032)
  7. 6.4.1 Global Antivirals Sales Value by Region: 2021-2026
  8. 6.4.2 Global Antivirals Sales Value by Region (2027-2032)
  9. 6.5 Global Antivirals Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Antivirals Sales Value (2021-2032)
  12. 6.6.2 North America Antivirals Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Antivirals Sales Value (2021-2032)
  15. 6.7.2 Europe Antivirals Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Antivirals Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Antivirals Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Antivirals Sales Value (2021-2032)
  21. 6.9.2 South America Antivirals Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Antivirals Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Antivirals Sales Value Share by Country, 2025 VS 2032
7 Antivirals Country-level Sales and Value Analysis
  1. 7.1 Global Antivirals Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Antivirals Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Antivirals Sales by Country (2021-2032)
  4. 7.3.1 Global Antivirals Sales by Country (2021-2026)
  5. 7.3.2 Global Antivirals Sales by Country (2027-2032)
  6. 7.4 Global Antivirals Sales Value by Country (2021-2032)
  7. 7.4.1 Global Antivirals Sales Value by Country (2021-2026)
  8. 7.4.2 Global Antivirals Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Antivirals Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Antivirals Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Antivirals Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Antivirals Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Antivirals Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Antivirals Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Antivirals Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Antivirals Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Antivirals Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Antivirals Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Antivirals Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Antivirals Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Antivirals Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Antivirals Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Antivirals Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Antivirals Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Antivirals Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Antivirals Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Antivirals Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Antivirals Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Antivirals Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Antivirals Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Antivirals Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Antivirals Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Antivirals Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Antivirals Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Antivirals Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Antivirals Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Antivirals Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Antivirals Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Antivirals Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Antivirals Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Antivirals Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Antivirals Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Antivirals Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Antivirals Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Antivirals Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Antivirals Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Antivirals Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Antivirals Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Antivirals Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Antivirals Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Antivirals Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Antivirals Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Antivirals Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Antivirals Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Antivirals Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Antivirals Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Antivirals Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Antivirals Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Antivirals Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Antivirals Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Antivirals Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Antivirals Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Antivirals Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Antivirals Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Antivirals Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Antivirals Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Antivirals Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Antivirals Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Antivirals Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Antivirals Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Antivirals Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Antivirals Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Antivirals Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Antivirals Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Antivirals Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Antivirals Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Antivirals Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Antivirals Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Antivirals Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Antivirals Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Antivirals Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Antivirals Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Antivirals Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Antivirals Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Antivirals Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Antivirals Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Antivirals Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Antivirals Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Antivirals Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Antivirals Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Antivirals Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Antivirals Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Teva Pharmaceutical Industries
  2. 8.1.1 Teva Pharmaceutical Industries Company Information
  3. 8.1.2 Teva Pharmaceutical Industries Business Overview
  4. 8.1.3 Teva Pharmaceutical Industries Antivirals Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Teva Pharmaceutical Industries Antivirals Product Portfolio
  6. 8.1.5 Teva Pharmaceutical Industries Recent Developments
  7. 8.2 Johnson & Johnson
  8. 8.2.1 Johnson & Johnson Company Information
  9. 8.2.2 Johnson & Johnson Business Overview
  10. 8.2.3 Johnson & Johnson Antivirals Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson & Johnson Antivirals Product Portfolio
  12. 8.2.5 Johnson & Johnson Recent Developments
  13. 8.3 Merck
  14. 8.3.1 Merck Company Information
  15. 8.3.2 Merck Business Overview
  16. 8.3.3 Merck Antivirals Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Merck Antivirals Product Portfolio
  18. 8.3.5 Merck Recent Developments
  19. 8.4 Mylan
  20. 8.4.1 Mylan Company Information
  21. 8.4.2 Mylan Business Overview
  22. 8.4.3 Mylan Antivirals Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Mylan Antivirals Product Portfolio
  24. 8.4.5 Mylan Recent Developments
  25. 8.5 Gilead Sciences
  26. 8.5.1 Gilead Sciences Company Information
  27. 8.5.2 Gilead Sciences Business Overview
  28. 8.5.3 Gilead Sciences Antivirals Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Gilead Sciences Antivirals Product Portfolio
  30. 8.5.5 Gilead Sciences Recent Developments
  31. 8.6 GSK
  32. 8.6.1 GSK Company Information
  33. 8.6.2 GSK Business Overview
  34. 8.6.3 GSK Antivirals Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GSK Antivirals Product Portfolio
  36. 8.6.5 GSK Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Antivirals Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Antivirals Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 F. Hoffmann-La Roche
  44. 8.8.1 F. Hoffmann-La Roche Company Information
  45. 8.8.2 F. Hoffmann-La Roche Business Overview
  46. 8.8.3 F. Hoffmann-La Roche Antivirals Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 F. Hoffmann-La Roche Antivirals Product Portfolio
  48. 8.8.5 F. Hoffmann-La Roche Recent Developments
  49. 8.9 Dr Reddy’s
  50. 8.9.1 Dr Reddy’s Company Information
  51. 8.9.2 Dr Reddy’s Business Overview
  52. 8.9.3 Dr Reddy’s Antivirals Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Dr Reddy’s Antivirals Product Portfolio
  54. 8.9.5 Dr Reddy’s Recent Developments
  55. 8.10 Cipla
  56. 8.10.1 Cipla Company Information
  57. 8.10.2 Cipla Business Overview
  58. 8.10.3 Cipla Antivirals Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Cipla Antivirals Product Portfolio
  60. 8.10.5 Cipla Recent Developments
  61. 8.11 Bristol-Myers-Squibb
  62. 8.11.1 Bristol-Myers-Squibb Company Information
  63. 8.11.2 Bristol-Myers-Squibb Business Overview
  64. 8.11.3 Bristol-Myers-Squibb Antivirals Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers-Squibb Antivirals Product Portfolio
  66. 8.11.5 Bristol-Myers-Squibb Recent Developments
  67. 8.12 Aurobindo Pharma
  68. 8.12.1 Aurobindo Pharma Company Information
  69. 8.12.2 Aurobindo Pharma Business Overview
  70. 8.12.3 Aurobindo Pharma Antivirals Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Aurobindo Pharma Antivirals Product Portfolio
  72. 8.12.5 Aurobindo Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antivirals Value Chain Analysis
  2. 9.1.1 Antivirals Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antivirals Sales Mode & Process
  6. 9.2 Antivirals Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antivirals Distributors
  9. 9.2.3 Antivirals Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst